+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leishmaniasis (Kala Azar) R&D Pipeline Analysis Report, H2-2018

  • ID: 4613898
  • Report
  • 100 pages
  • VPA Research
UP TO OFF
until May 30th 2019
1 of 4
Comprehensive Pipeline Review on Ongoing Clinical and Pre-Clinical Studies

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma
  • Daiichi Sankyo Co Ltd
  • Epichem
  • Immune Modulation Inc
  • Mologen AG
  • MORE
Leishmaniasis (Kala Azar) Drug Development Pipeline Study is the latest publication from this researcher with comprehensive information of Leishmaniasis (Kala Azar) pipeline products.

The Leishmaniasis (Kala Azar) pipeline guide presents complete overview of drugs currently being developed for Leishmaniasis (Kala Azar). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Leishmaniasis (Kala Azar) pipeline candidate.
Research and Development progress along with latest news related to each of the Leishmaniasis (Kala Azar) pipeline candidates is included.

Major companies participating in therapeutic development of Leishmaniasis (Kala Azar) are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Leishmaniasis (Kala Azar) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Leishmaniasis (Kala Azar) clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Leishmaniasis (Kala Azar) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Leishmaniasis (Kala Azar) pipeline report includes
  • Panorama of Leishmaniasis (Kala Azar) pipeline markets including statistics on therapeutic drugs and companies involved
  • Leishmaniasis (Kala Azar) Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Leishmaniasis (Kala Azar) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Leishmaniasis (Kala Azar) pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Leishmaniasis (Kala Azar) pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Leishmaniasis (Kala Azar) pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Leishmaniasis (Kala Azar) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Please Note: The report will be delivered in 2 working days after purchase
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma
  • Daiichi Sankyo Co Ltd
  • Epichem
  • Immune Modulation Inc
  • Mologen AG
  • MORE
I. Key Findings

1. Companies Investing in Leishmaniasis (Kala Azar) Pipeline include
Number of Companies with Leishmaniasis (Kala Azar) projects in pre clinical Development
Number of Companies with Leishmaniasis (Kala Azar) projects in Clinical Development
Leishmaniasis (Kala Azar) Pipeline Companies based in Americas
Leishmaniasis (Kala Azar) Pipeline Companies based in Europe
Leishmaniasis (Kala Azar) Pipeline Companies based in Asia Pacific
Leishmaniasis (Kala Azar) Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Leishmaniasis (Kala Azar) Pipeline Agents in pre clinical/ Discovery stage of Development
Leishmaniasis (Kala Azar) Pipeline Agents in Clinical Development stage
Leishmaniasis (Kala Azar) Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Leishmaniasis (Kala Azar) Pipeline agents

II. Insights into Leishmaniasis (Kala Azar) Pipeline -

1. Disease Overview
Introduction to Leishmaniasis (Kala Azar)
Symptoms and Causes of Leishmaniasis (Kala Azar)
Treatment or Prevention Options for Leishmaniasis (Kala Azar)
Other Details
2. Phase wise Pipeline Compounds
Leishmaniasis (Kala Azar) Pipeline Pre Clinical/ Discovery stage Drugs
Leishmaniasis (Kala Azar) Pipeline Phase 1 stage Drugs
Leishmaniasis (Kala Azar) Pipeline Phase 2 stage Drugs
Leishmaniasis (Kala Azar) Pipeline Phase 3 stage Drugs
Leishmaniasis (Kala Azar) Pipeline Pre Registration stage Drugs
3. Company wise Leishmaniasis (Kala Azar) Pipeline Compounds
4. Leishmaniasis (Kala Azar) Pipeline by Mechanism of Action

III. Leishmaniasis (Kala Azar) Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Leishmaniasis (Kala Azar) Pipeline Company Briefs

V. Latest News and Developments in Global Leishmaniasis (Kala Azar) Pipeline Market

VI. Appendix
1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Accelera; Anacor Pharmaceuticals Inc
  • Acea Biotech Inc
  • Advinus Therapeutics Ltd
  • Anacor Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • BioLingus AG
  • Celgene Global Health
  • Daiichi Sankyo Co Ltd
  • DetectoGen Inc
  • DNDi
  • Eisai Co Ltd
  • Epichem
  • Farmabrasilis
  • Fondation MEDINA
  • GlaxoSmithKline Plc
  • Immune Modulation Inc
  • London School of Hygiene and Tropical Medicine
  • Lypro Biosciences
  • ManRos Therapeutics
  • Merck KGaA
  • Mologen AG
  • Nanomerics
  • Oblita Therapeutics BVBA
  • Pfizer
  • Rakta Therapeutics Inc
  • Savant HWP Inc
  • Sequella Inc
  • Shionogi & Co Ltd
  • Takeda Pharmaceutical Company Ltd
  • The Kindred Association
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4613898
Adroll
adroll